
usd pm et
summari compani develop manufactur market proprietari specialti health care
product eye care women health
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
prior widespread concern
anticip fy oct revenu would
expand billion follow
growth fy expect sale
vision busi surgic
busi csi fall significantli short
initi expect due weak demand
vision consum like need contact
lens regardless econom condit
adopt expens daili lens
could fall short initi expect due
weaken consum sentiment
long-run see growth
increas adopt daili lens meanwhil
sale coo smaller csi busi like
neg impact world-wide declin
elect procedur driven
concern expect coo
gross margin expand slightli fy
fy fy
primarili due increas manufactur
costa rica plant grow sale
paragard high margin
think margin could flat slightli
lower growth daili lens lower
level elect procedur
think share trade near
fair valu grown key franchis
strateg expans invest
high-tech lens foreign market
taken market share larg competitor
win new wearer trade
exist user daili lens market
share gain mostli retain
consum stay contact len brand
year averag accord
select made expect
user transit daili contact
conveni hand
near-term growth could limit
competit dynam capac constraint
relat myday lens
risk recommend target price
slowdown demand daili contact lens
weaker-than-expect growth emerg
target price reflect
forward price-to-earnings multipl
ep estim
multipl toward high end
five-year rang higher
custom tend brand loyal come
contact lens howev off-set increas
competit contact lens new technolog
laser surgeri
jun ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview compani develop manufactur market health care
product two busi unit coopervis coopersurg csi account
net sale fy oct csi repres balanc
coopervis develop manufactur market broad rang single-us two-week
monthli contact lens world-wide vision care market contact len market two major
product categori spheric lens includ lens correct nearsighted farsighted
uncompl complex visual defect toric multifoc lens includ lens
addit correct nearsighted farsighted address complex visual defect
astigmat presbyopia sale fy product categori broke follow single-us
sphere non-singl use sphere toric len multi-foc len sale
geograph market america emea asia-pacif
coopersurg csi offer broad array product servic focus advanc health
famili portfolio product servic focus women health includ medic
devic fertil genom diagnost contracept csi offer product technolog servic
clinician patient world-wide csi collabor clinician identifi product new
technolog dispos product diagnost test sophist instrument equip
bring new product market csi also compet global vitro fertil ivf market
product portfolio ivf media assist reproduct technolog solut design enhanc
work fertil profession benefit famili
major develop novemb coopervis receiv fda approv misight len
first fda-approv product indic slow progress myopia children
treatment initi age expect avail unit state
novemb acquir paragard product line billion
paragard intrauterin devic iud hormone-fre long last revers contracept option
approv fda iud repres larg grow segment contracept market
acquisit compani mani substanti acquisit recent
market profil estim global soft contact len market grew calendar year
billion estim market share year ago tie alcon
number two johnson johnson estim market share primari growth driver
market continu daili lens grew year-over-year account
total market within daili lens silicon hydrogel lens growth driver
sale year-over-year advanc len technolog silicon hydrogel materi
could drive adopt contact lens compet technolog laser vision surgeri could
becom cheaper preval
financi trend fiscal year end octob sale billion
year-over-year reflect five-year compound annual growth rate compound-annual-growth-rate adjust ep grew
year-over-year reflect five-year compound-annual-growth-rate octob compani
low-to-moder level debt base net debt capit ratio leverag net debt
ebitda ratio
senior vice-president financ tax
chief account
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc march technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
mdr go effect may
follow vitro devic
regul ivdr goe effect
compani made much commentari
around introduct mdr
reason believ new regul could
neg impact industri exampl
juli submit letter
world trade organ request mdr
ivdr delay three year also
trade associ critic slow
piecem implement new
 health suppli index
rose slightli gain
 health
decreas composit index
neutral fundament outlook
health care suppli sub-industri next
current appear posit due strong
custom demand concern
possibl signific slowdown
environ think industri
perform well sever largest
firm industri sell elect product
use patient align
technolog sell orthodont align
cooper compani sell contact
lens base current expect
anticip ep growth
primarili due broad-bas margin expans
effort strong revenu growth align
technolog largest health care
yet also think increas
chanc econom slowdown would
neg impact demand health care
suppli relat lower urgenc medic need
elect procedur exampl sale
dentistri orthodontist suppli
compris signific portion health care
suppli could pressur
dental procedur may less essenti end
consum mean type
procedur could delay consum feel
sub-industri robust sale growth
emerg market recent year
expect continu key growth driver
sub-industri slowdown emerg
market could significantli dampen growth
health care suppli manufactur
long run howev see sustain growth
demand health care suppli driven
age longer-liv popul increas
 medic devic regul
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra reiter hold opinion share cooper compani
inc rais target price
ep estim multipl high end
five-year rang improv growth outlook lift
oct ep ep
jan-q ep vs higher estim jan-q sale
increas million coopervis revenu grew
million coopersurg csi revenu expand million jan-q
year-over-year pro-forma growth particularli strong emea asia
pacif respect daili lens continu signific growth
driver rest industri sale daili lens account
world-wide market estim user daili lens
make market also increas share daili
len market quarter ago /kevin huang cfa
et cfra maintain hold opinion share cooper compani
inc maintain target price
ep multipl higher end coo
five-year rang improv growth outlook oct-q
ep vs lower estim lower
oct ep initi ep oct-q
sale increas million coopervis revenu
million coopersurg csi revenu pro forma
million under-perform expect reason
higher-than-expect cost incur maintain custom servic
face coo distribut center upgrad activ rapid growth
adopt daili silicon hydrogel product cannib legaci product
estim current market share daili lens lower
market share reusabl lens space impli
signific opportun growth /kevin huang cfa
analyst research note compani news
et cfra keep hold opinion share cooper compani inc
rais target price base forward price-to-earnings
multipl ep estim jan-q ep
vs fell short estim light lower anticip
interest expens tax rate rais fy oct ep estim
fy ep jan-q sale increas
yoy million coopervis revenu grew
million coopersurg csi revenu grew million
manag dedic signific resourc acceler start-up
new manufactur line address capac constraint product myday
lens extrem strong demand meanwhil
launch misight underway complet train sale
repres misight februari expect neg
impact apr-q sale million howev csi like make
lost revenu fiscal /kevin huang cfa
et cfra maintain hold opinion share cooper compani
inc lower target price reflect
forward price-to-earnings multipl ep estim oct-q
ep vs estim lower fy oct
ep initi fy ep oct-q sale
increas organ million coopervis revenu
grew yoy organ million coopersurg csi revenu
grew organ million analyst question call focus
misight novemb becam first fda-approv contact len
slow myopia children conserv estim million sale
million world-wide fy think long-term opportun
product massiv although market take time develop
meanwhil demand myday lens continu acceler remain
focus allevi manufactur capac constraint expect
eas /kevin huang cfa
et cfra keep hold opinion share cooper compani inc
lift target price reflect forward price-to-earnings
multipl ep estim jul-q ep
vs higher estim lift fy oct ep
fy ep jul-q sale
increas organ million led coopervis
revenu grew yoy organ million
coopersurg csi revenu flat yoy organ million
compani oper margin bounc apr-q
prior-year-q due low expens growth growth led
continu uptak daili silicon len grew howev sale
emea region expect due lower stock level attribut
brexit concern sale paragard iud unexpectedli flat like
channel inventori contract decis halt
et cfra keep hold opinion share cooper compani inc
lift target price base multipl
ep estim multipl high
end rang apr-q ep vs
exceed consensu estim adjust fy oct ep
fy ep apr-q sale
increas organ million coopervis revenu
grew organ million coopersurg csi revenu
expand organ million oper margin declin
quarter prior-year period primarili due
neg impact currenc also due increas sale
market activ paragard devic see potenti
misight product specialti contact lens aim slow
progress myopia children increas invest misight
work fda /kevin huang cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
